Not necessarily the strongest absolute response. The most rational target could be the one where the difference in efficacy between Coramsine and the current best treatment is greatest. This presumably needs also to be blended with market potential to arrive at the optimal target.
- Forums
- ASX - By Stock
- SBP
- genentech up $11 billion
SBP
solbec pharmaceuticals limited
genentech up $11 billion, page-8
-
- There are more pages in this discussion • 7 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add SBP (ASX) to my watchlist
Currently unlisted public company.
The Watchlist
1CG
ONE CLICK GROUP LIMITED
Mark Waller, MD
Mark Waller
MD
Previous Video
Next Video
SPONSORED BY The Market Online